The University of Southampton
University of Southampton Institutional Repository

Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology

Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology
Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology

Body dysmorphic disorder (BDD) is characterized by a preoccupation with a perceived appearance flaw or flaws that are not observable to others. BDD is associated with distress and impairment of functioning. Psychiatric comorbidities, including depression, social anxiety, and obsessive-compulsive disorder are common and impact treatment. Treatment should encompass psychoeducation, particularly addressing the dangers associated with cosmetic procedures, and may require high doses of selective serotonin reuptake inhibitors∗ (SSRI∗) and protracted periods to establish full benefit. If there is an inadequate response to SSRIs, various adjunctive medications can be employed including atypical antipsychotics∗, anxiolytics∗, and the anticonvulsant levetiracetam∗. However, large-scale randomized controlled trials are lacking and BDD is not an approved indication for these medications. Oxytocin∗ may have a potential role in treating BDD, but this requires further exploration. Cognitive-behavioural therapy has good evidence for efficacy for BDD, and on-line and telephone-assisted forms of therapy are showing promise. CBT for BDD should be customized to address such issues as mirror use, perturbations of gaze, and misinterpretation of others' emotions, as well as overvalued ideas about how others view the individual.

antipsychotics, body dysmorphic disorder, cognitive-behaviour therapy, obsessive-compulsive disorder, serotonin reuptake inhibitors
0268-1315
61-75
Castle, David
ed99e035-e95a-466f-9dba-14bd2ce24c6f
Beilharz, Francesca
d23f53fd-26eb-4278-9c37-269e129b4a01
Phillips, Katharine A.
d465da11-8e86-4165-ac30-9806ee3bb4e7
Brakoulias, Vlasios
8de6a8cf-a840-48a0-9e0f-798dfb062e71
Drummond, Lynne M.
97e7b9e2-2aad-4728-a56d-1cb9fc93f71b
Hollander, Eric
f09fec3a-cb9c-43ad-8ea5-510ebf634dd8
Ioannidis, Konstantinos
82240a24-3153-45bb-bfaf-c6df9cd4f261
Pallanti, Stefano
d64e3605-980e-48a4-b70d-c70027986ec5
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Rossell, Susan L.
ad72bf17-bfca-4f38-a244-aee1c8964665
Veale, David
3f6d803f-cb91-4dab-86cb-de1bd2023d94
Wilhelm, Sabine
8c044282-752f-4458-a288-d8783c4e987f
Van Ameringen, Michael
db44aa61-019d-4841-a6cc-c746c8af3494
Dell'Osso, Bernardo
92b13aa3-d1bb-46d8-83cd-ed220cf450b5
Menchon, Jose M.
16ffa4cd-2b21-4476-a3e3-ef3d46473b32
Fineberg, Naomi A.
157dcac1-9fb2-4197-81f3-0167e1224f05
Castle, David
ed99e035-e95a-466f-9dba-14bd2ce24c6f
Beilharz, Francesca
d23f53fd-26eb-4278-9c37-269e129b4a01
Phillips, Katharine A.
d465da11-8e86-4165-ac30-9806ee3bb4e7
Brakoulias, Vlasios
8de6a8cf-a840-48a0-9e0f-798dfb062e71
Drummond, Lynne M.
97e7b9e2-2aad-4728-a56d-1cb9fc93f71b
Hollander, Eric
f09fec3a-cb9c-43ad-8ea5-510ebf634dd8
Ioannidis, Konstantinos
82240a24-3153-45bb-bfaf-c6df9cd4f261
Pallanti, Stefano
d64e3605-980e-48a4-b70d-c70027986ec5
Chamberlain, Samuel R.
8a0e09e6-f51f-4039-9287-88debe8d8b6f
Rossell, Susan L.
ad72bf17-bfca-4f38-a244-aee1c8964665
Veale, David
3f6d803f-cb91-4dab-86cb-de1bd2023d94
Wilhelm, Sabine
8c044282-752f-4458-a288-d8783c4e987f
Van Ameringen, Michael
db44aa61-019d-4841-a6cc-c746c8af3494
Dell'Osso, Bernardo
92b13aa3-d1bb-46d8-83cd-ed220cf450b5
Menchon, Jose M.
16ffa4cd-2b21-4476-a3e3-ef3d46473b32
Fineberg, Naomi A.
157dcac1-9fb2-4197-81f3-0167e1224f05

Castle, David, Beilharz, Francesca, Phillips, Katharine A., Brakoulias, Vlasios, Drummond, Lynne M., Hollander, Eric, Ioannidis, Konstantinos, Pallanti, Stefano, Chamberlain, Samuel R., Rossell, Susan L., Veale, David, Wilhelm, Sabine, Van Ameringen, Michael, Dell'Osso, Bernardo, Menchon, Jose M. and Fineberg, Naomi A. (2021) Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. International Clinical Psychopharmacology, 36 (2), 61-75. (doi:10.1097/YIC.0000000000000342).

Record type: Review

Abstract

Body dysmorphic disorder (BDD) is characterized by a preoccupation with a perceived appearance flaw or flaws that are not observable to others. BDD is associated with distress and impairment of functioning. Psychiatric comorbidities, including depression, social anxiety, and obsessive-compulsive disorder are common and impact treatment. Treatment should encompass psychoeducation, particularly addressing the dangers associated with cosmetic procedures, and may require high doses of selective serotonin reuptake inhibitors∗ (SSRI∗) and protracted periods to establish full benefit. If there is an inadequate response to SSRIs, various adjunctive medications can be employed including atypical antipsychotics∗, anxiolytics∗, and the anticonvulsant levetiracetam∗. However, large-scale randomized controlled trials are lacking and BDD is not an approved indication for these medications. Oxytocin∗ may have a potential role in treating BDD, but this requires further exploration. Cognitive-behavioural therapy has good evidence for efficacy for BDD, and on-line and telephone-assisted forms of therapy are showing promise. CBT for BDD should be customized to address such issues as mirror use, perturbations of gaze, and misinterpretation of others' emotions, as well as overvalued ideas about how others view the individual.

This record has no associated files available for download.

More information

Published date: 1 March 2021
Keywords: antipsychotics, body dysmorphic disorder, cognitive-behaviour therapy, obsessive-compulsive disorder, serotonin reuptake inhibitors

Identifiers

Local EPrints ID: 491847
URI: http://eprints.soton.ac.uk/id/eprint/491847
ISSN: 0268-1315
PURE UUID: d711cf56-09ef-41ef-8dcb-ee34d2baec04
ORCID for Samuel R. Chamberlain: ORCID iD orcid.org/0000-0001-7014-8121

Catalogue record

Date deposited: 04 Jul 2024 17:05
Last modified: 11 Jul 2024 02:07

Export record

Altmetrics

Contributors

Author: David Castle
Author: Francesca Beilharz
Author: Katharine A. Phillips
Author: Vlasios Brakoulias
Author: Lynne M. Drummond
Author: Eric Hollander
Author: Konstantinos Ioannidis
Author: Stefano Pallanti
Author: Samuel R. Chamberlain ORCID iD
Author: Susan L. Rossell
Author: David Veale
Author: Sabine Wilhelm
Author: Michael Van Ameringen
Author: Bernardo Dell'Osso
Author: Jose M. Menchon
Author: Naomi A. Fineberg

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×